H.pylori-L型对胃癌BGC-823细胞侵袭力影响的研究

目的研究幽门螺杆菌L型(Helicobacter pyloriL-form,H.pylori-L型)感染对胃癌BGC-823细胞侵袭力影响,探讨H.pylori-L型在胃癌发展中的作用和可能机制。方法将胃癌BGC-823细胞与H.pylori-L型按1:50、1:200和1:500的不同比例共培养24 h,进行以下实验:(1)应用具有聚碳酸酯和重建基底膜的Transwell小室细胞侵袭模型,观察与H.pylori-L型作用后胃癌BGC-823细胞的侵袭能力;(2)应用Western-blotting实验测定胃癌BGC-823细胞OPN和MMP2蛋白表达量的变化。结果 (1)Transwell侵袭实验发现随着胃癌BGC-823细胞与H.pylo-ri-L型细菌的浓度比例增大,胃癌BGC-823细胞穿透重建基底膜的数量逐渐增多,穿透重建基底膜的胃癌细胞数量在不同实验组之间的差异有统计学意义(F=24.78,P0.01);(2)Western-blotting实验发现,随着胃癌BGC-823细胞与H.pylori-L型比例增大,胃癌BGC-823细胞中OPN和MMP2的表达量逐渐增加,呈细菌浓度依赖性。结论 H.pylori-L型感染增强胃癌细胞的侵袭能力,具有细菌浓度依赖效应,其机制可能与其上调了胃癌细胞OPN、MMP2表达有关。     

RASSF1A和SKP2在胃癌中的表达及与幽门螺杆菌L型感染关系的研究

目的研究幽门螺杆菌L型(Helicobacter pyloriL-form,H.pylori-L型)感染,Ras相关区域家族1A基因(RASSF1A)和细胞S期激酶相关蛋白2(Skp2)在胃癌发生、发展中的作用及相互关系。方法应用革兰染色和免疫组织化学SP法检测50例胃癌组织及20例癌旁正常组织中的H.pylori-L型感染情况;同时应用逆转录聚合酶链式反应(RT-PCR)和免疫组织化学SP法检测上述组织中癌基因skp2和抑癌基因RASSF1A的表达。结果 50例胃癌组织标本中免疫组化及革兰染色H.pylori-L型同时阳性的病例有30例,胃癌组织和癌旁正常组织中H.pylo-ri-L型阳性率分别为60.0%和20.0%,2组之间差异有统计学意义(P<0.05)。胃癌组织中Skp2表达阳性率明显高于对照组(P<0.01);而RASSF1A表达阳性率明显低于对照组(P<0.01);H.pylori-L型阳性组的Skp2表达阳性率高于H.pylori-L型阴性组(P<0.05);H.pylori-L型阳性与Skp2的表达阳性呈正相关关系;RASSF1A的表达与H.pylori-L型阳性呈负相关关系。结论 H.pylori-L型感染在胃癌的发生发展过程中起重要的作用,其促进胃癌发生、发展的机制可能涉及上调Skp2的表达和下调RASSF1A的表达。     

胃癌组织中幽门螺杆菌L型感染及骨桥蛋白检测的意义

目的通过检测胃癌组织中幽门螺杆菌L(HP-L)型感染以及OPN的表达情况,探讨Hp-L型感染对胃癌侵袭、转移生物学行为的影响及可能机制。方法①应用革兰染色及免疫组化(SP)法检测120例胃癌组织中的Hp-L型感染情况;②应用免疫组化(SP)法检测胃癌组织中的OPN的表达。分析Hp-L型感染与OPN表达的关系以及和临床病理因素之间的关系。结果①120例胃癌组织中有88例革兰染色检出Hp-L型,其阳性率为73.3%(88/120);免疫组化Hp-L型抗原表达阳性率为70.8%(85/120),革兰染色Hp-L型检出和Hp-L型抗原表达同时阳性的病例有82例(两者同时阳性者为Hp-L型阳性),其阳性率为68.3%(82/120)。②胃癌组织中Hp-L型阳性组的OPN表达阳性率分别为70.73%(58/82),高于Hp-L型阴性组表达率,且有统计学意义(P<0.005)。经四格表资料χ2检验,胃癌组中Hp-L型阳性与OPN阳性表达呈正相关(r=0.27,P<0.001)。③胃癌中Hp-L型阳性与肿瘤的大小、癌细胞的血管侵袭、浸润深度及淋巴结转移具有相关性(P<0.001-P<0.05)。结论 Hp-L型感染是引起胃癌...     

TGM2对胃癌细胞BGC-823增殖、迁移和侵袭能力的影响

目的:转谷氨酰胺酶-2(transglutaminase-2,TGM2)是一种多功能的蛋白,在乳腺癌,胰腺癌,黑色素瘤和前列腺癌等肿瘤中高表达,而且和肿瘤的增殖和转移密切相关。本研究旨在探索TGM2对胃癌细胞BGC-823的增殖、迁移和侵袭能力的影响。方法:q RT-PCR、蛋白质印迹及免疫组化检测TGM2在胃癌细胞及组织中的表达情况;慢病毒转染胃癌细胞BGC-823以干扰TGM2的表达,荧光显微镜下观察转染效率,蛋白质印迹检测TGM2表达干扰效果;CCK-8法检测TGM2下调对BGC-823增殖能力的影响;Transwell法检测TGM2下调对BGC-823的迁移和侵袭能力影响;蛋白质印迹检测TGM2下调对转移和凋亡相关蛋白表达的影响。结果:TGM2在胃癌细胞和组织中均高表达,P0.01(q RT-PCR),P0.001(免疫组化);转染慢病毒后,荧光显微镜下观察结果显示转染效率超过90%,蛋白质印迹结果显示实验组sh TGM2-1的干扰效果最好,TGM2明显下调,差异具有统计学意义,P0.0001;CCK-8结果表明TGM2下调后,从细胞铺板第2d开始,实验组(sh TGM2-1)的细胞增殖倍数明显下降,P0.05(2d),P0.01(3d),P0.001(4d),P0.01(5d);Transwell结果显示,TGM2下调后,BGC-823的迁移和侵袭能力明显减弱,P0.001(迁移),P0.01(侵袭);蛋白质印迹结果显示,TGM2下调后,NF-κB和Bcl-2表达下调,而Bax表达上调,P0.05(NF-κB)、P0.001(Bcl-2)和P0.0001(Bax)。结论:TGM2下调能抑制胃癌细胞BGC-823的增殖、迁移和侵袭能力,并和NF-κB、Bcl-2的下调以及和Bax的表达水平上调有关,为胃癌的临床治疗提供了新靶点。     

靶向survivin的siRNA对胃癌BGC-823细胞增殖的影响

目的探讨干扰RNA沉默生存素（survivin）基因表达对人胃癌BGC-823细胞增殖和凋亡的影响。方法设计并合成3条靶向survivin的小分子干扰RNA（siRNA）,构建表达性干扰RNA质粒（shRNA）——shRNA-survivin-1、shRNA-survivin-2和shRNA-survivin-3,分别转染胃癌BGC-823细胞,实时定量PCR检测干扰RNA沉默survivin mRNA表达效果,Westernblot观察对胃癌BGC-823细胞survivin蛋白质表达的抑制,MTT（四甲基偶氮唑盐）比色法分析检测细胞生长抑制率,流式细胞计数检测各组细胞周期和凋亡率,探讨干扰RNA对胃癌BGC-823细胞生长的影响。结果在体外,shRNA-survivin-1有效沉默人胃癌BGC-823细胞survivin mRNA的表达,使sur-vivin mRNA相对水平明显降低（P〈0.05）,survivin蛋白质表达抑制,72h细胞生长抑制率达74.92%（P〈0.05）,shRNA-survivin-1使G2/M期细胞百分比明显增加,凋亡率显著增加（P〈0.05）。结论 shRNA-survivin-1可以沉默survivin基因的表达,可以显著抑制胃癌BGC-823细胞的增殖,在一定程度上诱导其自发凋亡。本研究为靶向sur-vivin的RNA干扰在胃癌的基因治疗提供了有力的理论依据和技术储备。     

Sprouty-2对胃癌细胞上皮间质转化及侵袭转移的影响

目的:研究Sprouty2(SPRY2)基因在胃癌肿瘤细胞上皮间质转化(EMT)和侵袭转移的影响。方法:体外培养人胃癌细胞(BGC-823),采用慢病毒介导的sh RNA沉默SPRY2基因,并用实时定量PCR与Western blot检测其SPRY2、E-钙黏蛋白(E-cadherin)、波形蛋白(vimentin)的表达,采用细胞划痕实验、Transwell实验检测SPRY2基因沉默后的胃癌细胞侵袭转移能力变化。结果:在慢病毒介导sh RNA沉默SPRY2基因的人胃癌BGC-823细胞中,SPRY2的m RNA和蛋白表达明显降低(P0.05),SPRY2沉默后人胃癌细胞E-cadherin的蛋白表达增多(P0.05),vimentin的蛋白表达减少(P0.05)。此外,SPRY2沉默后,胃癌细胞迁移能力和侵袭能力明显减弱(P值均P0.05)。结论:Sprouty-2基因通过调节E-cadherin与vimentin的表达参与胃癌细胞的上皮-间质转化,进而促进胃癌细胞的迁移与侵袭。     

胃癌组织中幽门螺杆菌L型感染与淋巴管形成关系的研究

目的 研究胃癌组织中D2-40、LYVE-1标记的微淋巴管密度(LVD)、血管内皮生长因子受体(VEGFR-3)表达与幽门螺杆菌L型(helicobacter pylori L-form,Hp-L型)感染之间的关系.方法 应用革兰染色和免疫组化SP法检测80例胃癌组织和25例对照组的Hp-L型感染,同时用免疫组化SP法检测上述组织的LVD值和VEGFR-3的表达,分析Hp-L型与LVD以及VEGFR-3表达的关系结果 胃癌组织中革兰染色L型检出阳性率为67.5％;免疫组化Hp-L型抗原表达阳性率为65％,两种方法检测同时阳性的病例50例,占62.5％.胃癌组的Hp-L型阳性率、LVD及VEGFR-3表达阳性率均高于对照组(P＜0.01);胃癌组中Hp-L阳性组的LVD值和VEGFR-3表达阳性率高于Hp-L阴性组.LVD与胃癌淋巴结转移具有一定关系.结论 Hp-L型感染与胃癌的发生、发展密切相关,Hp-L型可能是肿瘤淋巴管生成的重要促进因子,影响胃癌的侵袭和转移.     

c-Met与Fas在胃癌组织中的表达及其相关性

目的探讨c-Met和Fas在胃癌中的表达、临床意义及其相关性。方法采用免疫组化方法检测c-Met和Fas在正常胃黏膜（n=17）,胃癌旁组织（n=51）及胃癌组织（n=51）中的表达。结果在正常胃黏膜、胃癌旁组织及胃癌组织中,c-Met阳性率呈递增趋势,组间差异有统计学意义（χ^219.881,P〈0.01）;Fas阳性率有递减趋势,组间差异有统计学意义（χ^29.590,P〈0.01）。χ^2验显示c-Met在浸润深度和淋巴结转移组内阳性表达率组内差异有统计学意义（P〈0.05）,而在年龄、性别和组织分型组内差异无统计学意义（P〉0.05）;Fas在浸润深度组内阳性表达率组内差异有统计学意义（P〈0.05）,而在年龄、性别、组织分型和淋巴结转移组内差异无统计学意义（P〉0.05）。Spearman等级相关分析显示c-Met和Fas表达呈正相关（rs=0.599,P〈0.01）。结论c-Met过表达和Fas表达下调与胃癌的发生发展及浸润转移有关,c-Met表达可能是胃癌细胞逃逸Fas介导的细胞凋亡的一种机制。     

干扰SET8在胃癌细胞肿瘤进展和顺铂敏感性中的作用

目的 探究SET8对胃癌的进展以及对顺铂敏感性的影响。方法 采用免疫组织化学和蛋白质免疫印迹分析胃癌癌组织中SET8表达,采用qRT-PCR检测胃癌细胞中SET8 mRNA水平;胃癌BGC-823细胞转染SET8-shRNA后,采用CCK-8法检测细胞增殖,采用细胞集落形成实验检测细胞集落形成能力,采用transwell法检测细胞的迁移和侵袭能力;最后,采用CCK-8法检测干扰SET8表达对胃癌BGC-823细胞顺铂敏感性的影响。结果 胃癌组织及胃癌细胞中SET8表达明显升高;干扰SET8表达可抑制胃癌BGC-823细胞增殖、集落形成、迁移与侵袭,并提高胃癌细胞对顺铂敏感性。结论 干扰SET8表达可抑制胃癌细胞进展并提高顺铂敏感性。     

幽门螺杆菌对胃上皮细胞间隙连接超微结构的影响(英文)

通过实验和临床观察幽门螺杆菌（Helicobacter pylori）对胃上皮细胞间隙连接超微结构的影响,从细胞间隙连接角度探讨H.pylori致癌机制.将不同H.pylori菌株与BGC-823细胞共培养24h或48h,用原位固定与原位包埋法透射电镜观察细胞间隙连接超微结构变化.对70例胃癌患者,用快速尿素酶试验、碱性品红染色和14C尿素呼气实验检测H.pylori,PCR法检测H.pyloriCagA基因,及透射电镜观察胃上皮细胞间隙连接超微结构变化.结果显示,未加H.pylori组BGC-823细胞可见较多细胞连接及连接复合体,加H.pylori各组细胞的连接数、单位周长连接数与单位周长连接长度均小于未加H.pylori组,而细胞间隙最小宽度大于未加H.pylori组（P〈0.001或P〈0.005）,且CagA＋的NCTCJ99组、临床株GC01组和NCTC11639组细胞连接数、单位周长连接数均小于CagA-的NCTC12908组（P〈0.001或P〈0.05）,NCTCJ99组与临床株GC01组细胞单位周长连接长度短于NCTC12908组（P〈0.001）.胃癌患者H.pylori感染组细胞连接数、单位周长连接数与单位周长连接长度均小于无H.pylori感染组,细胞间隙最小宽度大于无H.pylori感染组（P〈0.001）,且CagA＋H.pylori感染者细胞连接数、单位周长连接数与单位周长连接长度均小于CagA-H.pylori感染者,细胞间隙最小宽度大于CagA-H.pylori感染者.上述结果表明,胃上皮细胞间隙连接改变与H.pylori感染,特别是CagA＋H.pylori感染有关.     

无花果枝提取物体外诱导胃癌BGC-823细胞凋亡的研究

为探讨新鲜无花果枝提取物(FBE)对体外培养的人胃癌细胞株BGC-823增殖和凋亡的影响,用不同浓度FBE处理胃癌BGC-823细胞,采用细胞形态学观察,细胞活力测定(MTY法)及免疫组织化学法检测增殖细胞核抗原(PCNA)表达情况来评价FBE对BGC-823细胞体外增殖的影响,应用流式细胞术的膜联蛋白V/碘化丙啶技术(Annexin V/PI法)检测FBE诱导BGC-823细胞体外凋亡的情况.形态学观察发现中高剂量(＞0.5mg/mL)组处理4 h细胞出现明显凋亡,24 h检测到中高剂量(＞0.5 mg/mE)组细胞增殖活力和增殖细胞核抗原表达显著降低(P＜0.05),流式细胞仪检测到FBE处理4 h所有剂量组细胞平均凋亡率(9.76%,10.87%,14.29%,49.67%,71.37%)均高于对照组(6.1%)(P＜0.05或P＜0.01),以上作用效果呈现剂量依赖性.以上结果说明无花果枝提取物能够通过诱导胃癌BGC-823细胞凋亡从而抑制其体外的生长与增殖.     

CDX2基因高表达对胃癌细胞生物学行为的影响

目的探讨尾侧型同源转录因子-2(CDX2)基因过表达对胃癌BGC-823细胞增殖、迁移、凋亡等生物学特征的影响。方法采用脂质体转染法建立CDX2基因过表达的胃癌BGC-823稳定细胞株,分别采用RT-PCR、Western blotting和免疫细胞化学等方法检测转染重组表达载体pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因及其蛋白的表达。MTT法检测CDX2基因过表达对细胞的增殖能力的影响;划痕实验检测CDX2过表达对细胞迁移能力的影响;流式细胞术检测CDX2过表达对细胞的凋亡的影响;应用基因芯片技术检测转染前后相关基因的差异表达。结果 RT-PCR及Western blotting检测结果显示,与对照组相比,转染pEGFP-C1/CDX2后,BGC-823细胞中CDX2基因和蛋白均呈高表达;CDX2过表达能明显降低转然组BGC-823细胞增殖能力和迁移能力;但对细胞凋亡影响不明显;基因芯片结果提示CDX2基因高表达能影响某些基因的表达。结论 CDX2过表达能明显抑制胃癌细胞增殖、降低迁移能力,提示CDX2在胃癌中可能发挥抑癌基因的作用。     

转录因子SOX2 对胃癌干细胞自我更新、增殖和迁移的影响

目的:检测SOX2在胃癌组织中的表达,探讨SOX2对胃癌干细胞自我更新、增殖和转移能力的影响。方法:采用免疫组化检测SOX2在胃癌及癌旁组织中的表达情况。通过肿瘤球形成实验富集、分离胃癌干细胞。构建SOX2过表达慢病毒并感染胃癌干细胞中,通过实时定量PCR和western bolt检测感染慢病毒后胃癌干细胞中SOX2表达情况。分别利用肿瘤球形成实验检测SOX2对胃癌肿瘤干细胞自我更新能力的影响,CCK-8实验检测SOX2对胃癌干细胞增殖能力的影响,流式细胞术分析SOX2对胃癌干细胞的细胞周期的影响,Transwell实验检测SOX2对胃癌干细胞转移能力的影响。结果:SOX2在胃癌组织中表达显著低于癌旁组织。肿瘤球形成实验能够有效富集胃癌细胞SGC-7901和BGC-823的干细胞。慢病毒载体感染能够显著增强SOX2在胃癌干细胞中的表达。过表达SOX2能够抑制胃癌干细胞的自我更新、增殖和侵袭能力。结论:SOX2在胃癌中发挥抑癌基因的功能,其机制可能通过抑制肿瘤干细胞的自我更新、增殖和侵袭转移能力而抑制胃癌的发生发展。     

Retracted: Curcumin derivative L6H4 inhibits proliferation and invasion of gastric cancer cell line BGC-823

Curcumin and its chalcone derivatives have well-known, explicit biological antitumor properties, such as instance antiproliferative and apoptotic effects via multiple molecular targets. In this study, we investigated the anticancer activity of curcumin derivative L6H4 (curcumin L6H4) on gastric cancer cells. Inhibitory effects of curcumin L6H4 on gastric cancer cells (BGC-823) were studied by the diphenyltetrazolium (MTT) assay, and cell apoptosis was detected by Annexin-V/propidium iodide (PI) staining and then analyzed by flow cytometry. A mouse xenotransplant gastric tumor model was established to detect the role of curcumin L6H4 in vivo. The apoptosis-related proteins p53, p21, Bax, and Bcl-2 in BGC-823 cells and mouse xenotransplant models treated with curcumin L6H4 were determined by Western blot analysis. Curcumin L6H4 can significantly inhibit the proliferation and induce the apoptosis of BGC-823 cells, thus enhancing the expression levels of p53, p21, Bax, and Bcl-2 noticeably in vivo and in vitro. Meanwhile, curcumin L6H4 can remarkably suppress the growth of tumor cells in animal models. These results suggest that curcumin derivative L6H4 has potent of antitumor properties in vitro or in vivo.     

Daidzein Induced Apoptosis via Down-Regulation of Bcl-2/Bax and Triggering of the Mitochondrial Pathway in BGC-823 Cells

Daidzein belongs to the group of isoflavones, found in a wide variety of plant-derived foods, especially in soybeans and soy-based foods. In this study, the effect of daidzein on human gastric carcinoma cells (BGC-823) and its mechanism were investigated. MTT assay was applied in the detection of the inhibitory effects of daidzein on cell proliferation. Hoechst–propidium iodide staining and flow cytometry were used to examine the apoptosis as well as the mitochondrial transmembrane potential. Western blotting was performed to detect the expression of apoptosis-associated proteins: cleaved PARP, cleaved caspase-9, cleaved caspase-3, Bcl-2, and Bax. Daidzein significantly inhibited the growth and proliferation of human gastric carcinoma cells (BGC-823) in a concentration- and time-dependent manner. Furthermore, it was found that an insult of daidzein to BGC-823 cells caused them to die by disruption of mitochondrial transmembrane potential, demonstrated not only by staining dead cells for phosphatidylserine but also by the up-regulation (cleaved PARP, cleaved caspase-9, cleaved caspase-3, Bax) and down-regulation (Bcl-2) of proteins associated with apoptosis and survival; whereas, the pan-caspase inhibitor z-VAD-fmk could partially rescue cells against damage of daidzein. Taken together, the results of this study demonstrate that daidzein significantly induces apoptosis via a mitochondrial pathway. Specifically, daidzein induced a change in the Bax/Bcl-2 ratios and activation of caspases-3 and -9 and the cleavage of PARP. Therefore, daidzein has the potential for use as a therapeutic agent for the treatment of gastric carcinoma.     

RASAL1 influences the proliferation and invasion of gastric cancer cells by regulating the RAS/ERK signaling pathway

The aim of this study was to investigate the biological characteristics of the RASAL1 gene in a well-differentiated gastric cancer cell line MKN-28 and a poorly differentiated gastric cancer cell line BGC-823 cells, using RNA interference and gene transfection technology, respectively. MKN-28 cells were transfected with the shRNA of RASAL1 and BGC-823 cells were transfected with the pcDNA 3.1 plasmid vector containing RASAL1. RT-PCR and western blotting were then used to detect the expression of RASAL1 mRNA and protein. The activities of RAS and extracellular signal-regulated kinase 1/2 were analyzed by the pull-down method and western blotting. The proliferate capacity, apoptosis rate, invasive and migratory potentials of MKN-28 or BGC-823 cells were also measured by Cell Counting Kit-8 cell proliferation assay, propidium iodide/Annexin V staining coupled with flow cytometry, and transwell chamber assays, respectively. Measurement of RASAL1 mRNA and protein expression in two cells revealed successful transfection of the shRNA of RASAL1 and RASAL1-pcDNA3.1 plasmid into these two cells. Moreover, decreased expression of RASAL1 in MKN-28 cells resulted in increased expression of RAS-GTP and p-ERK1/2. Interestingly, decreased expression of RASAL1 inhibited apoptosis and facilitated cell proliferation, invasion and migration. The increased expression of RASAL1 in BGC-823 cells caused declined expression of RAS-GTP and p-ERK1/2, as well as promoted apoptosis and restrained cell proliferation, invasion and migration. The down-regulation of RASAL1 promoted the proliferation, invasion and migration of gastric cancer MKN-28 cells, and up-regulation of RASAL1 inhibited the proliferation, invasion and migration of BGC-823 gastric cancer cells by regulating the RAS/ERK signaling pathway. Thus, our results suggest that RASAL1 may play an important role as a tumor suppressor gene in gastric cancer.